Biocryst Pharmaceuticals Inc
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies.
BCRX's revenue grew at a 61.8% CAGR over the last 6 years.
Current Price
$9.19
+0.33%Biocryst Pharmaceuticals Inc (BCRX) Insider Trades
BCRX Insider Trading Activity
Track insider trading transactions for Biocryst Pharmaceuticals Inc (BCRX). Monitor recent buys, sells, and option exercises by officers, directors, and 10% beneficial owners. Insider trading activity can signal management confidence or concern about a stock's future prospects.
Current stock price: $9.19. Market cap: $1.93B. This page displays the most recent insider transactions for BCRX, including the insider's name, title, transaction type (purchase, sale, or option exercise), number of shares, and total value. Filter transactions by type to focus on open-market purchases or sales.
Insider buying is often viewed as a bullish signal, as insiders are putting their own capital at risk. Conversely, large insider sales may warrant further investigation. Use GoodMoat's insider trading data alongside financial analysis, quality scores, and valuation tools for a comprehensive view of Biocryst Pharmaceuticals Inc's investment outlook.